ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 362

Methods to Efficiently Recruit Minority Patients with Gout for Clinic-Based Registries

Giovanni Adami1, Giovanna Rosas 2, Joshua Melnick 3, Jeffrey Foster 2, Elizabeth Rahn 2, Amy Mudano 4, Jeffrey Curtis 2, Tony Merriman 5, S Louis Bridges 4 and Kenneth Saag 2, 1University of Verona, Verona, Italy, 2University of Alabama at Birmingham, Birmingham, AL, 3University of Alabama at Birmingham, Birmimgham, AL, 4University of Alabama at Birmingham, Birmingham, 5University of Otago, Birmingham, AL

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: African-Americans, gout, registry and research methods

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: Metabolic & Crystal Arthropathies Poster I: Clinical

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Gout is frequently misdiagnosed and/or miscoded, making approaches to identifying eligible patients for observational and interventional studies more challenging. Ethnic and racial minorities are under-represented in many gout studies. Methods to better identify minorities and patients with confirmed gout will ensure studies have better validity and more generalizability. We defined efficient methods for identifying African Americans (AA) interested in participating in a gout registry who satisfied the American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) gout classification criteria.

Methods: We identified all AA patients seen at University of Alabama at Birmingham from 01/09/2017 to 31/08/2018 with an ICD 9/10 code for gout. Patients not “opted out” by their primary care provider (PCP) were invited to participate via electronic letters and/or mailed invitations. Those interested underwent detailed medical record review followed by phone contact to determine gout eligibility. Those with a high likelihood of meeting gout diagnostic criteria were invited for an in-person visit to confirm diagnosis (Figure 1). We compared descriptive characteristic of participants enrolled in the registry with the larger populations of potentially eligible subjects.

Results: From 3,032 AA patients with an ICD 9 /10 gout diagnosis we generated a random sample of 400 patients. 5 patients were excluded by their PCPs, thus 395 patients were preliminarily eligible who we attempted to contact. 1 patient (< 1%) communicated lack of interest, 19 (4.8%) were unreachable, 322 (81.5%) did not respond to our invitation, and 53 (13.4%) expressed preliminary interest and underwent medical record review. We successfully scheduled 30 subjects for a registry visit, 24 completed the visit, and 23 (6% of initial sample) satisfied 2015 ACR/EULAR gout classification criteria (see Table 1). We found no significant difference in age, sex, and the number of medical encounters in the last year between enrolled patients and the remaining population.

Conclusion: We present an efficient strategy for identifying and recruiting AA patients with ACR/EULAR classified gout into a population-based registry. Among a randomly selected cohort of AAs with an initial ICD 9/10 diagnosis code of presumed gout, slightly under 15% expressed interest and eventually 6% satisfied the 2015 ACR/EULAR criteria and successfully enrolled in the registry. Our experience emphasizes a potential approach as well as some challenges in creating a generalizable gout registry of under-represented minority patients.

Figure 1. Sequential steps employed to recruit African Americans to a gout registry

Table 1. Characteristics of African Americans -n = 24- who completed an scheduled in-person visit for a gout registry


Disclosure: G. Adami, None; G. Rosas, None; J. Melnick, None; J. Foster, None; E. Rahn, None; A. Mudano, None; J. Curtis, AbbVie, 2, 5, Abbvie, 2, 5, AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Lilly, Janssen, Myriad, Pfizer, Regeneron, Roche, and UCB, 2, 5, Amgen, 2, 5, Amgen Inc., 2, 5, BMS, 2, 5, Bristol-Myers Squibb, 2, 5, Corrona, 2, 5, Crescendo, 2, 5, Eli Lilly, 2, 5, Eli Lilly and Company, 2, 5, Genentech, 2, 5, Janseen, 5, Janssen, 2, 5, Janssen Research & Development, LLC, 2, Lilly, 2, 5, Myriad, 2, 5, Patient Centered Outcomes Research Insitute (PCORI), 2, Pfizer, 2, 5, Radius Health, Inc., 9, Regeneron, 2, 5, Roche, 2, 3, 5, Roche/Genentech, 5, UCB, 2, 5; T. Merriman, Ardea Biosciences, 2, 5, AstraZeneca, 2, 5, Ironwood Pharmaceuticals, 2; S. Bridges, None; K. Saag, Abbvie, 5, AbbVie, 5, Amgen, 2, 5, Ampel, 2, Bayer, 5, Gilead, 5, Horizon, 2, 5, Ironwood/AstraZeneca, 2, 5, Kowa, 5, kowa, 5, Mereo, 2, Radius, 5, Radius Health, 2, 5, Roche/Genentech, 5, SOBI, 2, 5, Sobi, 2, 5, Takeda, 2, 5, Teijin, 5, Tejin, 5.

To cite this abstract in AMA style:

Adami G, Rosas G, Melnick J, Foster J, Rahn E, Mudano A, Curtis J, Merriman T, Bridges S, Saag K. Methods to Efficiently Recruit Minority Patients with Gout for Clinic-Based Registries [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/methods-to-efficiently-recruit-minority-patients-with-gout-for-clinic-based-registries/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/methods-to-efficiently-recruit-minority-patients-with-gout-for-clinic-based-registries/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology